Cephalon bought Gemin X with a $225 M upfront and milestones that could reach $300 M. Cephalon obtains Gemin's phase IIb candidate obatoclax (GX15-070) for small cell lung cancer (SCLC), which it hopes can become a first line therapy for the disease. SCLC currently has few good options and it has been more than 25 years since there has been a therapeutic advance in this area. Cephalon will also pick up Gemin's teglarinad (GMX1777) that is in preclinicals. See Fierce Biotech.
Posted by Bruce Lehr March 26th 2011.